

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM625781

<b>SUBMISSION TYPE:</b>	RESUBMISSION		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>RESUBMIT DOCUMENT ID:</b>	900584291		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Athyrium Opportunities II Acquisition LP		12/01/2020	Limited Partnership: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Bionpharma Inc.		
<b>Street Address:</b>	600 Alexander Road, Suite 2-4B		
<b>City:</b>	Princeton		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	08540		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	Bionpharma Healthcare LLC		
<b>Street Address:</b>	600 Alexander Road, Suite 2-4B		
<b>City:</b>	Princeton		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	08540		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86477035	BIONPHARMA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7036106200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	7036106100		
<b>Email:</b>	boxip@hoganlovells.com		
<b>Correspondent Name:</b>	Greta D. Feldman of Hogan Lovells US LLP		
<b>Address Line 1:</b>	8350 Broad Street, 17th Floor		
<b>Address Line 2:</b>	Attn: Box Intellectual Property		
<b>Address Line 4:</b>	Tysons, VIRGINIA 22102		
<b>ATTORNEY DOCKET NUMBER:</b>	036639.000019		

<b>NAME OF SUBMITTER:</b>	Greta D. Feldman of Hogan Lovells US LLP
<b>SIGNATURE:</b>	/Greta D. Feldman/
<b>DATE SIGNED:</b>	02/11/2021
<b>Total Attachments: 3</b> source=MidCap - Bion - TM Termination_Athyrium#page1.tif source=MidCap - Bion - TM Termination_Athyrium#page2.tif source=MidCap - Bion - TM Termination_Athyrium#page3.tif	

RELEASE OF SECURITY INTEREST IN TRADEMARKS

December 1, 2020

WHEREAS, Bionpharma Inc. and Bionpharma Healthcare LLC (each individually a “Grantor” and collectively, “Grantors”) granted a security interest in and lien upon certain trademarks and related rights to Athyrium Opportunities II Acquisition LP, as collateral agent (in such capacity, the “Collateral Agent”) for the benefit of the Secured Parties, as set forth in the Credit and Security Agreement dated as of December 1, 2015, as amended, among the Collateral Agent, the Grantors and the lenders party thereto and the Intellectual Property Security Agreement dated as of December 1, 2015, between the Grantors and the Collateral Agent (the “IP Security Agreement,” and collectively, the “Security Agreements”). Capitalized terms used but not defined herein shall have the meaning given such terms in the Security Agreements.

WHEREAS, an executed copy of the IP Security Agreement was recorded in the United States Patent and Trademark Office (the “USPTO”) on January 4, 2016 at Reel 5701, Frame 0004;

WHEREAS, Grantors have requested that Collateral Agent, on behalf of the Secured Parties, release their interest in the Intellectual Property Collateral including the trademarks more fully identified in Schedule A annexed hereto and made a part hereof;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Collateral Agent, on behalf of the Secured Parties, hereby:

1. terminates, discharges, releases and reassigns to Grantors, any and all liens, security interests, right, title and interest of the Secured Parties pursuant to the Security Agreements in and to the Intellectual Property Collateral, including, without limitation, the trademarks more fully identified in Schedule A annexed hereto and made a part hereof, without recourse or representation or warranty, express or implied, of any kind;
2. agrees that any power of attorney or similar rights granted by Grantors to the Secured Parties pursuant to or in connection with the Security Agreements is terminated;
3. authorizes and requests that the USPTO note and record the existence of the release hereby given; and
4. agrees that this Release of Security Interest in Trademarks may be filed with the USPTO or any other governmental office to evidence the termination and release granted by this agreement.


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, Collateral Agent, on behalf of the Secured Parties, has caused this Release of Security Interest in Trademarks to be executed by its duly authorized corporate officer as of the date first set forth above.

ATHYRIUM OPPORTUNITIES II ACQUISITION  
LP, a Delaware limited partnership

By: Athyrium Opportunities Associates II LP, Its  
General Partner

By: Athyrium GP Holdings LLC, Its General Partner

By:   
Name: Andrew C. Hyman  
Title: Authorized Signatofy

**SCHEDULE A  
TO  
RELEASE OF SECURITY INTEREST IN TRADEMARKS**

**LIST OF TRADEMARKS AND TRADEMARKS APPLICATIONS**

Description	Application Number	Application Date
BIONPHARMA (word mark)	US 86477035	Dec 10, 2014